Key result
A 37-year-old female receiving rituximab for rheumatoid arthritis developed enteroviral meningoencephalitis that completely resolved following treatment with intravenous immunoglobulin.
Why the study?
Enteroviral meningoencephalitis is a rare complication of rituximab reported in hematologic malignancies, but had not been reported in patients receiving rituximab for rheumatoid arthritis.
Case Report (n=1)
Patients on rituximab for rheumatoid arthritis are susceptible to severe complications of typically self-limited viral infections like enterovirus, which can be successfully treated with IVIG.
Answers are grounded in this paper and cite their sources.
May warrant vigilance for enteroviral meningoencephalitis in rituximab-treated RA patients with neurologic symptoms; leaves open true incidence and risk factors.
Enteroviral meningoencephalitis is a rare complication of rituximab therapy that has been described in the treatment of hematologic malignancies. We report the first case of enteroviral meningoencephalitis in a patient receiving rituximab for the treatment of rheumatoid arthritis. A 37-year-old female treated with rituximab for severe rheumatoid arthritis presented with fever, headache, confusion, and tremor. Magnetic resonance imaging (MRI) of the brain was unrevealing. Cerebrospinal fluid showed a lymphocytic pleocytosis and multiplex polymerase chain reaction (PCR) was positive for enterovirus. She was treated with intravenous immunoglobulin (IVIG) for five days and had significant improvement in symptoms. Rituximab is an anti-CD20 monoclonal antibody that induces B-cell depletion and possible hypogammaglobulinemia, putting patients at increased risk for viral infections. We present this case to highlight that patients on rituximab, regardless of the indication for use, are susceptible to severe complications of otherwise typically self-limited viral infections. Furthermore, we describe the potential use of IVIG in treating these patients.
No takes yet. Share an insight, caveat, or question.
Cook et al. (2021) conducted a case report in Rheumatoid arthritis and enteroviral meningoencephalitis (n=1). Rituximab was evaluated on Symptom resolution. A 37-year-old female receiving rituximab for rheumatoid arthritis developed enteroviral meningoencephalitis that completely resolved following treatment with intravenous immunoglobulin.
Synapse has enriched 10 related papers. Consider them for comparative context: